Research Analysts Issue Forecasts for XENE FY2025 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the biopharmaceutical company will earn ($2.41) per share for the year. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share.

Other equities analysts have also recently issued reports about the company. Raymond James reiterated an “outperform” rating and set a $50.00 price target on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Needham & Company LLC reissued a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $56.00.

Xenon Pharmaceuticals Trading Up 0.5 %

Xenon Pharmaceuticals stock opened at $39.19 on Thursday. Xenon Pharmaceuticals has a 12-month low of $35.53 and a 12-month high of $50.99. The firm has a 50 day simple moving average of $40.28 and a 200-day simple moving average of $40.80.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same quarter in the prior year, the business posted ($0.73) earnings per share.

Insider Transactions at Xenon Pharmaceuticals

In related news, Director Gary Patou sold 4,891 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total transaction of $200,922.28. Following the transaction, the director now directly owns 23,573 shares of the company’s stock, valued at approximately $968,378.84. The trade was a 17.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Sherry Aulin sold 18,709 shares of Xenon Pharmaceuticals stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The disclosure for this sale can be found here. 5.52% of the stock is currently owned by insiders.

Institutional Trading of Xenon Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Blue Trust Inc. raised its stake in shares of Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 641 shares in the last quarter. Avior Wealth Management LLC bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $101,000. nVerses Capital LLC acquired a new stake in shares of Xenon Pharmaceuticals in the third quarter worth $102,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Xenon Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 487 shares during the period. Finally, KBC Group NV grew its stake in Xenon Pharmaceuticals by 39.8% in the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 780 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.